Decreased acid secretion is thought to adversely affect the absorption of calcium and increase the risk of fracture by causing a decrease in bone density. The meta-analyses of observational studies conducted with heterogeneous populations showed that the risk of any fracture (OR: 1.29, 95% CI: 1.18-1.41) and hip fracture (OR: 1.23, 95% CI: 1.11-1.36) slightly increased with PPI depending on the dose and regardless of duration; but no risk increase was detected with H2RA use (1,2).
other hand, no risk increase was found with H2RA use (OR: 1.71, 95% CI: 0.97-3.01) (6) .
Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are other problems that are associated with the treatment of acid inhibition. In the meta-analysis of observational studies, a slight increase in the risk of CAP was observed with the use of PPI in early stages (<1 month) and especially with high doses (OR: 1.38, 95% CI: 1.1-1.76). In the longterm use of PPI therapy, risk increase was found to be non-significant for CAP (OR: 1.1, 95% CI: 0.9-1.2) or HAP (OR: 1.04, 95% CI: 0.58-1.88). It was shown that neither of the two drug groups differed for HAP in hospitalized patients (RR: 1.06, 95% CI: 0.73-1.52) in the meta-analysis of randomized controlled trials (7-9).
Though it was reported that the inhibition of gastric acid negatively affected the absorption of vitamin B12, folic acid, vitamin D, and calcium, no difference was found between the initial and end of follow-up levels in a five-year LOTUS study in which PPI and surgical arms were compared (10) .
No increase in the risk of premalignant gastric lesions was observed in the meta-analysis of randomized controlled trials in which PPI treatment was given to H. pylori negative patients for more than 6 months (11).
The relationship between hypomagnesaemia and acid inhibitor therapy was considered to be an idiosyncratic situation. In the cross-sectional and case-controlled studies, in which the presence of hypomagnesaemia-related disease and the use of medication are taken as exclusion criteria, no relationship was found between magnesium deficiency and PPI (12, 13) . However, in two cross-sectional studies that were conducted recently, it was noted that the risk increased with the use of PPI in patients using diuretics (p<0.001), having GFR<60, and over 65 years of age (p=0.03) (14, 15) .
In quasi-experimental studies that were conducted with omeprazole and ranitidine, and included a small number of patients, it was indicated that the absorption and levels of zinc could be reduced (16, 17) .
It has been suggested that hypergastrinemia induced with PPI therapy increases the risk of fundic polyps by causing proliferation in parietal cells. In the meta-analysis of 5 observational studies that were evaluated through a systematic literature review, the use of PPI was found to increase the risk of fundic polyps (OR: 2.89, 95% CI: 1.62-5.16) (18) (19) (20) (21) (22) . When its relationship with duration was considered, it was observed that long-term (>1 year) PPI use increased the risk of fundic polyp 6-fold, but there was no risk in shorter use (OR: 1.03, 95% CI: 0.64-1.69) (21, 22) .
In the meta-analysis of 17 randomized controlled trials in which reflux patients were included and PPI was compared with the arms of surgery or placebo, no difference was observed in terms of all of the adverse effects (RR: 1.04, 95% CI: 0.98-1.11) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . In the meta-analysis of 6 randomized trials in which H2RA and placebo were compared, the incidence of all of the adverse effects was similar among the arms (RR: 1.13, 95% CI: 0.97-1.31) (39) (40) (41) (42) (43) (44) . In the meta-analysis of 8 randomized trials that compared PPI and H2RA, no difference was found between the two groups of drugs in terms of all of the adverse effects (RR: 0.94, 95% CI: 0.86-1.02) and serious adverse effects (RR: 0.93, 95% CI: 0.85-1.01) (39, (45) (46) (47) (48) (49) (50) (51) .
RECOMMENDATIONS
• There is a slight increase which is proportional to the dose in the risk of fracture in patients taking a PPI. Such a risk is not observed for patients using H2RA (Level of evidence: 3a). However, the presence of osteoporosis in patients with indication should not prevent PPI use. • The use of PPIs or H2RA does not have differences in terms of the incidence of side effects when compared with a placebo (Level of evidence: 1a). However, attention should be paid in terms of fracture risk*, CAP*, spontaneous bacterial peritonitis*, C. Difficile infection*, and bacterial overgrowth** (Level of evidence: 3a*, 2a**).
